# First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Source: https://onco.cc/trials/nct07136779/  
OnCo record `nct07136779` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VBC101 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.

## Summary

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT07136779 by VelaVigo Bio Inc, with 310 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-07-01. Interventions recorded: VBC101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07136779
- Phase: 1/2
- Setting: PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES
- Sponsor: VelaVigo Bio Inc
- Enrolled: 310

## Sources

- ClinicalTrials.gov NCT07136779: https://clinicaltrials.gov/study/NCT07136779

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07136779.json